Search - tctmd.com

Displaying 101 - 120 of 134

Sort: Relevancy | Date

Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS

News Conference News ACC 2018

Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS

Michael O'Riordan

March 12, 2018

Bariatric Surgery: Cardiometabolic Benefits Down, but Not Out, at 5 Years

News Daily News

Bariatric Surgery: Cardiometabolic Benefits Down, but Not Out, at 5 Years

Michael O'Riordan

January 18, 2018

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

December 26, 2017

Statins and Diabetes: Causal Link Reinforced in New Analysis

News Daily News

Statins and Diabetes: Causal Link Reinforced in New Analysis

Michael O'Riordan

October 25, 2017

Secondary Prevention Lagging Behind in Women With Established Coronary Disease

News Daily News

Secondary Prevention Lagging Behind in Women With Established Coronary Disease

September 22, 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

News Conference News ESC 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Michael O'Riordan

August 29, 2017

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

News Features

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Michael O'Riordan

May 23, 2017

Trans Fat Ban Led to Tangible CVD Benefits, New York State Analysis Shows

News Daily News

Trans Fat Ban Led to Tangible CVD Benefits, New York State Analysis Shows

Michael O'Riordan

April 12, 2017

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

News Daily News

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Michael O'Riordan

February 03, 2017

News Features

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

December 30, 2016

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

December 30, 2016

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

News Daily News

PCSK9的变体与低LDL胆固醇和糖尿病风险增加相关

Michael O'Riordan

December 01, 2016

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

News Daily News

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

Michael O'Riordan

December 01, 2016

News Daily News

Nearly 40% of Diabetic Patients Not Treated With Statins: PINNACLE Registry

Michael O'Riordan

September 13, 2016

News Daily News

遗传上更高的血脂水平似乎可预防 2 型糖尿病

August 04, 2016

News Daily News

Los Niveles Altos de Lípidos Dictados Genéticamente Parecen Proteger Frente a la Diabetes Tipo 2

August 04, 2016

News Daily News

Genetically Dictated Higher Lipid Levels Seem to Protect Against Type 2 Diabetes

August 04, 2016

News Daily News

AstraZeneca Strives to Block Generic Crestor as Observers Call Foul

Michael O'Riordan

July 13, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.